Review article · 12 May 2026
Research articlePublished 14 Sep 2011
Assessment of Cholesterol Absorption and Synthesis in Japanese Patients with Type-2 Diabetes and Lipid-Lowering Effect of Ezetimibe
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Aims: Cholesterol absorption is reported as an independent risk factor for cardiovascular disease. However, factors related to cholesterol absorption have not been fully examined in patients with type-2 diabetes (T2DM). The aim of this study was to assess cholesterol absorption/synthesis markers and the effect of an inhibitor of cholesterol absorption, ezetimibe, in patients with T2DM with hyper-low-density lipoprotein cholesterolemia. Methods: We included 59 patients treated with statins (S group) and 121 patients who were not receiving any lipidlowering treatments (N group). Levels of cholesterol absorption and synthesis markers were compared between the 2 groups and between subjects in the N group with and without microvascular complications. The lipid-lowering effect of ezetimibe treatment (10 mg/day for 12 weeks) was examined in 70 patients with high levels of low-density lipoproteincholesterol (LDL-C). These patients were divided into the monotherapy (M) group (n = 57; ezetimibe treatment only) and the combination therapy (C) group (n = 13; ezetimibe and statin treatment). Results: The levels of cholesterol absorption and synthesis markers were higher and lower, respectively, in patients in the S group than in the N group (both p < 0.05). In the N group, the cholesterol-absorption marker levels were higher in patients with microvascular complications than in those without (p < 0.05). Ezetimibe decreased total cholesterol and LDL-C levels by 13% and 21% and 11% and 16% in patients in the M group and C group, respectively (all p < 0.05). In patients of the M group, ezetimibe decreased the levels of remnant-like particle-cholesterol, high-sensitivity c-reactive protein, and triglycerides (TG; only in cases with TG ≥ 150 mg/dL) by 16%, 5%, and 21%, respectively, and increased high-density lipoprotein-cholesterol by 6.8% (all p 0.05). Conclusions: Ezetimibe may be a useful therapeutic option to prevent micro- and macrovascular complications for dyslipidemia in patients with T2DM.
Keywords
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Internal Medicine.
Mini review · 10 Mar 2026
Low-Dose Aspirin in Coronary Artery Disease: Evidence and Implications
Mini review · 15 Feb 2026
Extracellular Vesicles: A Key Regulator of Macrophage Polarization During Bacterial Infection
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternal Medicine
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Tomoko Nakagami”
- BylineArticles whose byline prints “Yayoi Yamamoto”
- BylineArticles whose byline prints “Sayaka Fukushima”
- BylineArticles whose byline prints “Junko Oya”
- BylineArticles whose byline prints “Yasuhiko Iwamoto”
- BylineArticles whose byline prints “Yasuko Uchigata”